19 results about "Mucoadhesive polymers" patented technology

An ocular insert, comprising: (a) at least one first mucoadhesive polymer selected from the group consisting of hyaluronic acid or sodium hyaluronate, polyvinylpyrrolidone, carboxyl methyl cellulose, and a combination thereof; (b) at least one second mucoadhesive polymer selected from the group consisting of hydroxyethyl guar, hydroxypropyl guar (HP-guar), hydroxypropyl methylcellulose (HPMC), and a combination thereof; (c) at least one plasticizer and (d) olopatadine in an amount from 2% to 20% by weight of the ocular insert, wherein the ocular insert has no visible recrystallization under examination with a polarized light microscope at approx. 100× magnification, wherein the ocular insert has a single-layer, homogeneous structure, wherein the at least one first mucoadhesive polymer and the at least one second mucoadhesive polymer are together present in the ocular insert in an amount of from about 75% to about 90% by weight of the ocular insert.

The present invention relates to nucleic acid fragment-encapsulated polymer nanoparticles and a method of preparing the same. The polymer may be a mucoadhesive polymer and specifically chitosan, and the nucleic acid fragment may be polydeoxyribonucleotide (PDRN). The nucleic acid fragment-encapsulated polymer nanoparticles may be used as an eye drop. Since the nucleic acid fragment-encapsulated polymer nanoparticles is capable of adhering to the mucus in the eyes, nucleic acid fragments inside the nanoparticles can be slowly released into the ocular mucous membrane. In addition, since nucleic acid fragment-encapsulated polymer nanoparticles can exhibit high efficiency in the eyes even with a small dose of drug, patient convenience can be increased or costs can be reduced.

A solid mucoadhesive composition comprising or consisting of (a) at least one active agent, preferably at least one perfume or fragrance molecule; (b) at least one carrier; and (c) at least one mucoadhesive polymer, wherein the carrier is selected from the group comprising silicon dioxide, silica and silicates.

A composition or a contraceptive composition comprising a mucoadhesive polymer in a physiologically acceptable carrier, wherein the mucoadhesive polymer consists of 4 to 20 monomers units linked to each other via ether, ester or amide bonds, which monomer units are selected from the list consisting of amino functionalised C6 sugars, C6 sugars, amino functionalised C5 sugars, C5 sugars, amino acids, fatty acid derivatised C6 sugars and fatty acid derivatised C5 sugars and its uses thereof.

The present invention is directed to an ophthalmic emulsion. The emulsion has a unique combination of ingredients that promotes the thermal stability of small oil droplets within the emulsion. The emulsion also includes a mucoadhesive polymer that aid in delivering a lipid to the ocular surface.

The present invention is directed to an ophthalmic emulsion. The emulsion has a unique combination of ingredients that promotes the thermal stability of small oil droplets within the emulsion. The emulsion also includes a mucoadhesive polymer that aid in delivering a lipid to the ocular surface.

Provided herein is an ophthalmic composition, comprising an aqueous solution, comprising (i) a pharmaceutically effective amount of a phosphorylcholine-tuftsin conjugate, (ii) between 0.1 and 5% weight per weight (w / w) of a viscosity enhancer, and (iii) between 0.1 and 5% w / w of a mucoadhesive polymer. Provided herein is a synergistic preservative composition comprising a phosphorylcholine-tuftsin conjugate and BAK. Furthermore, a pharmaceutical composition (e.g. ophthalmic composition) comprising an effective amount of the preservative composition is also povided. A method of using the ophthalmic composition such as for treating or preventing ocular inflammation in a subject in need thereof is also provided. Furthermore, method of using the ophthalmic composition such as for enhancing ocular bioavailability of a phosphorylcholine-tuftsin conjugate within a subject is also provided.

The invention features a mucosal coating composition including: (i) water: (ii) at least one mucoadhesive polymer / polysaccharide (e.g., a concentration between 0.1-20% w / v); and (iii) at least one surfactant (e.g., a concentration between 0.005-5% w / v). Exhibit long-lasting residence times on mucosal tissues and prophylactic protection against transmucosal pathogens.

In an embodiment, a method of treating tinnitus is disclosed that includes administering to an individual in need of treatment from 50 to 260 IU of merotocin over a 24 hour period. The method may include administering the merotocin intranasally. The method may include administering the merotocin in a powdered or aerosolized form to the upper nasal cavity of the individual. The method further includes administering the merotocin in a composition which further includes a thickener present in an amount of from 5% to 12% by weight of the composition, said thickener having a viscosity of from 4,000 to 12,000 cps. The composition may include a mucoadhesive polymer. The method may include administering the merotocin in a solution suitable for parenteral administration.

The present disclosure relates aqueous composition comprising a mucoadhesive polymer and clay particles and methods of treating or preventing infection.

In an embodiment, a method of treating tinnitus is disclosed that includes administering to an individual in need of treatment from 50 to 260 IU of merotocin over a 24 hour period. The method may include administering the merotocin intranasally. The method may include administering the merotocin in a powdered or aerosolized form to the upper nasal cavity of the individual. The method further includes administering the merotocin in a composition which further includes a thickener present in an amount of from 5% to 12% by weight of the composition, said thickener having a viscosity of from 4,000 to 12,000 cps. The composition may include a mucoadhesive polymer. The method may include administering the merotocin in a solution suitable for parenteral administration.

The present invention relates to an adhesive intraoral disc for sustained release of cannabinoids. The disc comprises one or more cannabinoids and consists of a mucosal contact layer having a mucosal contact surface usable to be fixed to the gingiva of a person requiring relief or treatment of a medical condition, comprising one or more mucosal adhesive polymers that enable the adhesive intraoral disc to adhere to the gingiva for an extended period. Furthermore, the disc comprises a non-mucosal adhesive module fused with the mucosal contact layer, comprising a solid tablet composition that enables the non-mucosal adhesive module to dissolve for an extended period when the adhesive intraoral disc adheres to the gingiva. The present invention is particularly useful for the relief or treatment of ulcers.

A dissolvable medical device for placing on the outer exposed surface of the eye to deliver a drug to the eye comprises: a polymeric film has sufficient dimensions to cover a cornea when applied to an eye and the polymeric film comprising one or more mucoadhesive polymers. The polymeric film dissolves between 15 minutes to 120 minutes to release the mucoadhesive and the pharmaceutically active agents after applying the polymeric film to the eye. The dissolved polymeric film is not impeding visualization of ocular tissue while maintaining a protective film on outer surface of the eye.

The present invention relates to nucleic acid fragment-encapsulated polymer nanoparticles and a method of preparing the same. The polymer may be a mucoadhesive polymer and specifically chitosan, and the nucleic acid fragment may be polydeoxyribonucleotide (PDRN). The nucleic acid fragment-encapsulated polymer nanoparticles may be used as an eye drop. Since the nucleic acid fragment-encapsulated polymer nanoparticles is capable of adhering to the mucus in the eyes, nucleic acid fragments inside the nanoparticles can be slowly released into the ocular mucous membrane. In addition, since nucleic acid fragment-encapsulated polymer nanoparticles can exhibit high efficiency in the eyes even with a small dose of drug, patient convenience can be increased or costs can be reduced.

A mucoadhesive composition and method for the administration of the pharmaceutically effective agents is provided. Specifically, a mucoadhesive composition, composed of a mucoadhesive polymer and a plurality of active agents having different water solubility embedded therewithin; and use thereof such as for the treatment of a disease is provided.

The present invention provides compositions for controlled local deposition of one or more drugs within an individual. More specifically, described herein are compositions comprising a) a polyethylene glycol (PEG) composition having a first low molecular weight PEG (Mw of 200-500 Da) and a second low molecular weight PEG (Mw of 500-2000 Da) and b) a mucoadhesive polymer. Alternatively, the compositions can comprise a) a polyethylene glycol (PEG) composition having a first low molecular weight PEG (Mw of 200-500 Da) and a second low molecular weight PEG (Mw of 500-2000 Da), b) a water insoluble polymer and c) a mucoadhesive polymer. In addition, the compositions can further comprise one or more drugs. Also provided are methods of making and administering the compositions described herein, which are used as biodegradable, injectable, mucoadhesive, low viscosity pastes.

To provide a mucoadhesive polymer capable of cross-linking the cervical-vaginal mucus layer without aggregation of the mucus, or with a lesser degree of aggregation compared to a prior composition.SOLUTION: The disclosure relates to a vaginal contraceptive composition comprising one or more active ingredients and a physiological acceptable gelling agent, wherein at least one of the one or more active ingredients is a mucoadhesive polymer, wherein the mucoadhesive polymer has a molecular weight between 20,000 Da and 100,000 Da, wherein the mucoadhesive polymer consists of a plurality of monomer units linked to each other via ether bonds, ester bonds, amide bonds, or combinations hereof, wherein the monomer units are selected from C6 sugars, amino-functionalised C6 sugars, amino acids, or combinations hereof, and wherein at least 50% of the monomer units comprise at least one amino group.SELECTED DRAWING: Figure 1A

Articles that include from 20 wt-% to 45 wt-% of one or more plant based oils based on the total weight of the article; from 50 wt-% to 70 wt-% of one or more polymer film formers based on the total weight of the article; and from 5 wt-% to 15 wt-% of one or more humectants based on the total weight of the article. Further articles comprises this combination of oil, film former and humectant as a first layer adjacent to which a second layer comprises a mucoadhesive polymer. The articles may be used to prevent formation or maintenance of biofilm in an oral tissue, affect hydration loss in an oral tissue, affect lubricity or lubriciousness in an oral tissue or treat xerostomia or dry mouth. Preferred polymer film formers include pullulan, xanthan gum, HP guar, ethyl cellulose and carrageenan.

The application discloses a mucous membrane-adhesive polymeric microcarrier loaded with disodium cladribine tetrasodium and a preparation method and application thereof. Sodium alginate is modified by phenylboronic acid to obtain a PBA-Alg polymer; disodium cladribine tetrasodium is mixed with the polymer to obtain a precursor solution; microdroplets are formed by a microfluidic electrospray technology and sprayed into a calcium ion crosslinking solution to be solidified to obtain the microcarrier. In the microcarrier, the phenylboronic acid groups form reversible borate ester bonds with cis-diol groups in the disodium cladribine tetrasodium molecules, so that stable anchoring and continuous release of the drug are realized. The phenylboronic acid groups on the surface of the microcarrier can form dynamic covalent bonds with sialic acid residues in ocular surface mucin, so that long-acting adhesion on the ocular surface is realized; meanwhile, the borate ester bonds are oxidatively cleaved in the presence of excess active oxygen on the ocular surface, so that the active oxygen is consumed and inflammation is inhibited. The microcarrier has a highly uniform size and shear thinning characteristics, and can be safely, comfortably, efficiently and low-frequency used for the treatment of ocular surface diseases such as dry eye.